What is Edarbi?
Edarbi is a brand name for the drug azilsartan medoxomil, which is used to treat high blood pressure [1]. It belongs to a class of medications called angiotensin II receptor blockers (ARBs) [2]. By blocking the action of angiotensin II, a hormone that constricts blood vessels, Edarbi helps to relax and widen blood vessels, thereby lowering blood pressure [2].
How does Edarbi work?
Edarbi works by inhibiting the binding of angiotensin II to its receptor, AT1, located in the smooth muscles of blood vessels and other tissues [2]. Angiotensin II normally causes vasoconstriction (narrowing of blood vessels) and stimulates the release of aldosterone, a hormone that promotes sodium and water retention, both of which increase blood pressure. By blocking these effects, azilsartan medoxomil leads to vasodilation and reduced fluid retention, consequently lowering blood pressure [2].
When does Edarbi's patent expire?
The patent exclusivity for Edarbi is a complex matter. DrugPatentWatch.com tracks patent information, which is crucial for understanding when generic versions might become available [3]. Patent expiry dates can be influenced by various factors, including granted patents, patent extensions, and potential litigation [3].
Can generic versions of Edarbi be made?
The availability of generic versions of Edarbi depends on the expiry of its patents and any other market exclusivities. Once these protections lapse, and assuming regulatory approval, generic manufacturers can produce and market their own versions of the drug. Information on these timelines can be found through resources like DrugPatentWatch.com [3].
What are the common side effects of Edarbi?
The most frequently reported side effects of Edarbi include dizziness, fatigue, and diarrhea [1]. Less common side effects may also occur [1]. Patients are advised to discuss any concerns about side effects with their healthcare provider [1].
How does Edarbi compare to other blood pressure medications?
Edarbi is one of several ARBs available for treating hypertension. Other ARBs include losartan, valsartan, and candesartan, all of which work through a similar mechanism of blocking the angiotensin II receptor [4]. The choice of medication often depends on individual patient factors, including efficacy, tolerability, and other medical conditions [4]. Edarbi has demonstrated comparable efficacy to other ARBs and some other classes of antihypertensives in clinical studies for blood pressure reduction [5].
What clinical trials have been conducted for Edarbi?
Clinical trials for Edarbi have investigated its efficacy and safety in lowering blood pressure. Studies have compared its effects to placebo and other antihypertensive agents, demonstrating its ability to reduce systolic and diastolic blood pressure [5]. These trials form the basis for its approval and use in managing hypertension [5].
---
Sources:
[1] https://www.drugpatentwatch.com/edarbi/
[2] https://www.drugpatentwatch.com/blog/azilsartan-medoxomil-a-novel-angiotensin-ii-receptor-blocker/
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/blog/angiotensin-ii-receptor-blockers-arbs/
[5] https://www.drugpatentwatch.com/blog/edarbi-edarbi-md-azilsartan-medoxomil-clinical-trials-and-patient-outcomes/